Rep. Porter calls on HHS in­spec­tor gen­er­al to in­ves­ti­gate FDA-Bio­gen ties pri­or to Aduhelm's ap­proval

Fol­low­ing the House Over­sight Com­mit­tee’s call to in­ves­ti­gate the ap­proval and price of Bio­gen’s new Alzheimer’s drug, Rep. Katie Porter (D-CA) is now call­ing on HHS’ in­spec­tor gen­er­al to in­ves­ti­gate the cozy re­la­tion­ship be­tween the FDA and Bio­gen ahead of that ap­proval.

The fall­out over the Aduhelm ap­proval con­tin­ues in her let­ter Tues­day as Porter calls for a full re­view of all agency prac­tices in meet­ing with phar­ma­ceu­ti­cal com­pa­nies and to es­tab­lish new in­ter­nal poli­cies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER